Advertisement
India will resume the export of surplus COVID-19 vaccines in October under the ”Vaccine Maitri” programme and to meet its commitment to the COVAX global pool.
COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and WHO.
“What is clear now, that the export ban on vaccine manufacturing is going to be lifted… India is going to play one of the most important roles on planet earth in bringing this pandemic to an end. Because of its innovation, because of the investments that have been made over a long period of time in expanding vaccine manufacturing capacity,” United States Agency for International Development (USAID) Administrator, Samantha Power said.
Related Articles
Advertisement
“I think it’s also India as an inspiration. You know, we — and I’ll stay on COVID, just because it’s certainly the topic of our time, along with the climate. But in both domains, in fact. You know, as India innovates in its transition to renewables, on the climate front, as it extends its vaccine manufacturing capacity,” Power said, participating in the USAID discussion with former US Ambassador to India Richard Verma.
Speaking at the virtual event, Power said, “Not only for COVID vaccines but now to make itself again a hub for vaccinations for other diseases that have been concentrated in the developed world. That manufacturing capacity, that’s giving a lot of countries ideas. We are talking of Rwanda, Senegal, we just, through the Development Finance Corporation, made a big investment in South Africa.”
“Once India is in a position, you know, to move past COVID in a way that, of course, is in the interests of the Indian people to do. And we’re seeking to support them to do. For it to bring its expertise to bear on how a country like South Africa can extend already what it is doing in the manufacturing space,” Power said.